Invitrogen™ CD133 (Prominin-1) Monoclonal Antibody (13A4), eBioscience™, Invitrogen™

Beschreibung

The 13A4 MAb recognizes mouse Prominin-1 (sometimes referred to as CD133 and, in the case of human orthologue, as AC133), a 115-120 kDa pentaspan transmembrane (5-TM) domain glycoprotein. Prominin-1 is expressed on primitive cells such as hematopoietic stem and progenitor cells, neural and endothelial stem cells, retina and retinoblastoma, as well as developing epithelium. To date, the function and ligand of Prominin-1 are unknown. The 13A4 antibody does not cross react with rat, human, chicken, or Drosophila antigen but has been reported to work in canine/dog. Applications Reported: The 13A4 antibody has been reported for use in flow cytometric analysis (∽0.25-1 μg/million cells), immunoprecipitation (∽10-25 μg/mL), immunoblotting (WB) (∽1-5 μg/mL), and immunohistochemical staining (∽1-10 μg/mL). Applications Tested: The 13A4 antibody has been tested by flow cytometric analysis of mouse bone marrow cells. This can be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

The CD133 (AC133) antigen is a 97 kDa glycoprotein, with 5 transmembrane domains, that shows up as a 120 kDa band on protein gels due to glycosylation. CD133 is a cell surface marker expressed by immature hematopoietic stem cells but not mature blood cells. In addition to hematopoietic stem and progenitor cells, CD133 has been found to be a marker for other stem and progenitor cells including neural and embryonic stem cells. CD133 has been shown to be expressed in cancers, including some leukemias and brain tumors, that may be derived from stem cells. Low level expression could also be detected in the kidney, pancreas, placenta, and fetal liver. Mutations in this gene have been shown to result in retinitis pigmentosa and Stargardt disease. Expression of the CD133 gene is also associated with several types of cancer. CD133 is expressed from at least five alternative promoters that are expressed in a tissue-dependent manner, and multiple transcript variants encoding different isoforms have been found.